FDA discussions pave pathway for U.S. clinical trial preparations LONDON, Nov. 15, 2021 (GLOBE NEWSWIRE) — Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “ Company” or “Small Pharma”), a neuropharmaceutical company focused on psychedelic-assisted therapies today confirms, following positive discussions with the U.S. Food and Drug Administration (the “FDA”), that preparations are now underway…


Previous articleRed Light Holland Psilocybin Truffles, Sold in The Netherlands, Complete First Evaluation Under a Health Canada Approved cGMP Laboratory
Next articleMindMed Launches Study of Low-Dose LSD Effects on Sleep and Cognitive Measures